Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Pharmacol. 2009 Aug;9(4):501-6. doi: 10.1016/j.coph.2009.05.005. Epub 2009 Jun 17.

The adenosinergic immunomodulatory drugs.

Author information

1
New England Inflammation and Tissue Protection Institute, Northeastern University, 113 Mugar Health Science Building, 360 Huntington Avenue, Boston, MA 02115, United States. a.ohta@neu.edu

Abstract

Hypoxia-driven increase of extracellular adenosine in local tissue microenvironments of inflamed and cancerous tissues plays a critical role in the regulation of tissue destruction by activated immune cells. Accumulated data suggest that injection or consumption of A2A adenosine receptor (A2AR) antagonists may represent a drug treatment that diminishes adenosine-mediated immunosuppression. Since this, in turn, enhances the immune response, inhibition of adenosine-A2AR signaling may be a promising approach to enhance anti-tumor or anti-pathogen immune response. Patients with disorders characterized by excessive inflammation may be at risk to A2AR antagonists (e.g. caffeine) because of the effect to increase inflammatory damage secondary to enhanced immunity. On the other hand, enhancement of hypoxia-adenosinergic immunomodulatory pathways may be beneficial to prevent inflammatory tissue destruction.

PMID:
19539527
PMCID:
PMC2756083
DOI:
10.1016/j.coph.2009.05.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center